Clinical Trials Logo

Mucopolysaccharidosis Type IIIA clinical trials

View clinical trials related to Mucopolysaccharidosis Type IIIA.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06181136 Recruiting - Clinical trials for Mucopolysaccharidosis Type IIIA

Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)

Start date: December 7, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open-label, Phase 1/2 study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and exploratory clinical efficacy of DNL126 in participants with Sanfilippo syndrome Type A (MPS IIIA). The core study period is 25 weeks (approximately 6 months) and is followed by a 72-week (approximately 18 month) open-label extension (OLE).